微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 86.22% | 0.29% | -0.42% | 13/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 86.58% | 0.41% | 1.66% | 11/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 85.17% | 1.06% | -1.25% | 11/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 86.25% | 2.01% | 0.33% | 12/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 85.97% | 1.88% | -0.3% | 10/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 86.23% | 2.46% | 2.31% | 10/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 84.28% | -0.08% | -0.32% | 11/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 84.55% | 1.12% | 0.2% | 13/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 84.38% | 1.34% | 0.26% | 14/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 84.16% | 0.79% | -0.23% | 13/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 84.35% | -0.04% | 0.88% | 16/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 83.61% | -2.27% | 0.42% | 16/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 83.26% | -3.73% | -0.28% | 16/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 83.5% | -3.81% | -1.06% | 17/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 84.39% | -2.85% | -1.36% | 15/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 85.56% | -2.7% | -1.08% | 17/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 86.49% | -1.4% | -0.36% | 13/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 86.81% | -1.29% | -0.06% | 13/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 86.86% | 0.31% | -1.21% | 11/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 87.93% | 0.5% | 0.24% | 12/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 87.72% | 0.62% | -0.25% | 10/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 87.94% | 1.44% | 1.55% | 9/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 86.6% | 0.25% | -1.03% | 9/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 87.49% | 1.03% | 0.36% | 9/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 87.18% | 0.74% | 0.57% | 6/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 86.69% | 0.09% | 0.35% | 7/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 86.38% | -0.1% | -0.25% | 7/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 86.6% | -0.04% | 0.07% | 10/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 86.54% | -0.01% | -0.09% | 6/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 86.61% | 0.03% | 0.16% | 7/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 86.47% | -0.38% | -0.19% | 6/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 86.63% | -0.5% | 0.1% | 9/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 86.55% | -0.35% | -0.04% | 5/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 86.58% | -0.09% | -0.25% | 4/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 86.8% | 1.34% | -0.31% | 4/158 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 87.07% | 2.1% | 0.26% | 5/158 | 48.52% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 86.85% | 2.16% | 0.22% | 4/158 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 86.65% | 2.72% | 1.17% | 4/158 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 85.65% | 2.48% | 0.44% | 3/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |